Clinical Evidence
Our trials have collected over 2.5 million patient breaths over 10 years, which now drive our diagnostic AI algorithms
Grounded in robust science over 10 years, developed on a unique dataset
From research in
Primary Care
Secondary Care
With data from
Multiple ethnicities
All ages (5-96y)
Multiple countries
Control groups of healthy subjects
All major cardiorespiratory conditions
Key Completed Studies
2024
Completed
N-WATCH Phase 1
Early-stage longitudinal sudy evaluating the ease of use and efficacy of N-Tidal in suspected paediatric asthma
2022
Completed
Cardiorespiratory Diagnostic Study (CARES)
A 740 patient study across the UK in all conditions which can present with breathlessness and cough.
clinicaltrials.gov2022
Completed
Asthma Breathing Record Study (ABRS)
A longitudinal study in patients with severe asthma
clinicaltrials.gov2018
Completed
General Breathing Record Study (GBRS)
A longitudinal study in patients with COPD, asthma, pneumonia, breathing pattern disorder, MND and heart failure
clinicaltrials.gov2018
Completed
COPD Breathing Record Study 2 (CBRS2)
A follow-up longitudinal observational study in patients with severe COPD
clinicaltrials.gov2016
Completed
COPD Breathing Record Study (CBRS)
A longitudinal study in patients with severe COPD
clinicaltrials.govOngoing & Upcoming Studies
2024
Ongoing
Lung-Tech Trial
Evaluation of novel asthma diagnostic technologies for integration into clinical practice
clinicaltrials.gov2024
Ongoing
Beyond FRONTIER
A large 900 patient study evaluating N-Tidal Diagnose efficacy in early COPD diagnosis.
2025
Upcoming
N-WATCH Phase 2
A pivotal study of 420 paediatric patients to validate TidalSense's asthma diagnostic algorithms in children.
2025
Upcoming
CORMORANT
A large 500 patient study to evaluate the real-world efficacy of N-Tidal Diagnose in a primary care setting.
"TidalSense have shown enthusiasm not only for thoroughly validating the diagnostic performance of N-Tidal Diagnose with high quality studies like Beyond-FRONTIER, but also for better characterising the underlying physiology of the capnography waveform. They share the ambition of many respiratory physicians and physiologists of being able to detect COPD at an earlier stage than currently possible, and therefore open up the possibility of earlier intervention and better outcomes for patients."
Prof Mike Crooks
Hull/York NHS Trust,
COPD service lead
Recent Publications & Reports
Talker et al., 2024
This multi-study publication demonstrates the ability for N-Tidal to diagnose all stages of COPD and identify disease severity (J COPD)
Learn moreTalker et al., 2023
This multi-study publication demonstrates 91% accuracy (AUC = 0.97) in diagnosing severe COPD, from a single N-Tidal recording (Respiratory Research)
Learn moreTalker et al., 2024
Diagnosis of Asthma-COPD overlap syndrome (AUC=0.96) using N-Tidal (American Thoracic Society)
Learn moreBroomfield et al., 2024
Prediction of small airways disease in asthma using interpretable machine learning (American Thoracic Society)
Learn moreLim et al., 2023
Research showing ability to predict smoking-related airway remodelling in COPD using N-Tidal (Thorax, British Thoracic Society)
Learn moreBroomfield et al., 2023
Research showing accurate classification (AUC=0.91) of asthma, from a single N-Tidal recording (Thorax, British Thoracic Society)
Learn moreSupported by leading clinicians
"We have run several clinical studies with the N-Tidal on patients with severe asthma and other respiratory disorders. I believe that TidalSense's technologies have the potential to transform the way we diagnose and treat many of these respiratory conditions."
Prof. Anoop Chauhan, MBE
Director of Research and Innovation, Portsmouth Hospitals
University NHS Trust
"60% to 70% of patients with COPD are undiagnosed and many are misdiagnosed or diagnosed late. This is a massive clinical problem. N-Tidal is a really exciting solution to this problem and if it becomes part of the annual physical, doctors will be able to monitor their patients more effectively and pick up early disease that may have been missed in the past. I think that N-Tidal's high patient acceptance and ease of use means that it's going to have a big effect clinically."
Prof. Scott T. Weiss
Professor of Medicine
Harvard Medical school